Publications
-
Accessory splenules in autoimmune hemolytic anemia.
Logan A,
Berube C, Gotlib J.
Am J Hematol.
2013;
88
(2):
156
-
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
Mesa RA,
Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Hare T, Erickson-Viitanen S, Sun W, Sandor V, Levy RS, Kantarjian HM, Verstovsek S.
J Clin Oncol.
2013;
31
(10):
1285-92
-
International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.
Gotlib J,
Pardanani A, Akin C, Reiter A, George T, Hermine O, Kluin-Nelemans H, Hartmann K, Sperr WR, Brockow K, Schwartz LB, Orfao A, Deangelo DJ, Arock M, Sotlar K, Horny HP, Metcalfe DD, Escribano L, Verstovsek S, Tefferi A, Valent P.
Blood.
2013;
121
(13):
2393-401
-
DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups.
Ohgami RS,
Ma L, Ren L, Weinberg OK, Seetharam M, Gotlib JR, Arber DA.
Br J Haematol.
2012;
159
(2):
182-90
-
ICON: Eosinophil Disorders.
Valent P,
Klion AD, Rosenwasser LJ, Arock M, Bochner BS, Butterfield JH, Gotlib J, Haferlach T, Hellmann A, Horny HP, Leiferman KM, Metzgeroth G, Matsumoto K, Reiter A, Roufosse F, Rothenberg ME, Simon HU, Sotlar K, Vandenberghe P, Weller PF, Gleich GJ.
World Allergy Organ J.
2012;
5
(12):
174-181
-
Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders.
Gotlib J,
Akin C.
Semin Hematol.
2012;
49
(2):
128-37
-
Next-generation sequencing in hematologic malignancies: what will be the dividends?
Merker JD,
Valouev A, Gotlib J.
Ther Adv Hematol.
2012;
3
(6):
333-9
-
Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia.
Medeiros BC,
Kohrt HE, Gotlib J, Coutre SE, Zhang B, Arber DA, Zehnder JL.
Am J Hematol.
2012;
87
(1):
45-50
-
World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
Gotlib J,
Am J Hematol.
2012;
87
(9):
903-14
-
A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia.
Zhang B,
Ng D, Jones C, Oh ST, Nolan GP, Salehi S, Wong W, Zehnder JL, Gotlib J.
Blood.
2011;
118
(26):
6988-90
-
Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors.
Pollyea DA,
Raval A, Kusler B, Gotlib JR, Alizadeh AA, Mitchell BS.
Hematol Oncol.
2011;
29
(3):
157-60
-
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.
Pardanani A,
Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A.
J Clin Oncol.
2011;
29
(7):
789-96
-
World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
Gotlib J,
Am J Hematol.
2011;
86
(8):
677-88
-
Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory.
Merker JD,
Jones CD, Oh ST, Schrijver I, Gotlib J, Zehnder JL.
J Mol Diagn.
2010;
12
(1):
58-64
-
Eosinophilic myeloid disorders: new classification and novel therapeutic strategies.
Gotlib J,
Curr Opin Hematol.
2010;
17
(2):
117-24
-
JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
Oh ST,
Gotlib J.
Expert Rev Hematol.
2010;
3
(3):
323-37
-
Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge.
Arredondo AR,
Gotlib J, Shier L, Medeiros B, Wong K, Cherry A, Corless C, Arber DA, Valent P, George TI.
Am J Hematol.
2010;
85
(8):
600-6
-
Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.
Oh ST,
Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs KD, Merker JD, Zehnder JL, Nolan GP, Gotlib J.
Blood.
2010;
116
(6):
988-92
-
Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience.
Kohrt HE,
Patel S, Ho M, Owen T, Pollyea DA, Majeti R, Gotlib J, Coutre S, Liedtke M, Berube C, Alizadeh AA, Medeiros BC.
Am J Hematol.
2010;
85
(11):
877-81
-
A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes.
Gotlib J,
Lavori P, Quesada S, Stein RS, Shahnia S, Greenberg PL.
Am J Hematol.
2009;
84
(1):
15-20
-
Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system.
Weinberg OK,
Seetharam M, Ren L, Seo K, Ma L, Merker JD, Gotlib J, Zehnder JL, Arber DA.
Blood.
2009;
113
(9):
1906-8
-
Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation.
Abrahamsson AE,
Geron I, Gotlib J, Dao KH, Barroga CF, Newton IG, Giles FJ, Durocher J, Creusot RS, Karimi M, Jones C, Zehnder JL, Keating A, Negrin RS, Weissman IL, Jamieson CH.
Proc Natl Acad Sci U S A.
2009;
106
(10):
3925-9
-
Molecular stratification of patients with normal karyotype acute myeloid leukemia based on initial assessment of FLT3-internal tandem duplication status at first complete remission.
Medeiros BC,
Gotlib J, Zehnder J.
Leuk Lymphoma.
2009;
50
(5):
851-3
-
Monoclonal antibodies against IREM-1: potential for targeted therapy of AML.
Korver W,
Zhao X, Singh S, Pardoux C, Zhao J, Guzman ML, Sen S, Yonkovich S, Liu S, Zhan X, Tomasevic N, Zhou C, Gros D, Jordan CT, Gotlib J, Hsi ED, Abo A.
Leukemia.
2009;
23
(9):
1587-97
-
Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens.
Fan AC,
Deb-Basu D, Orban MW, Gotlib JR, Natkunam Y, O'Neill R, Padua RA, Xu L, Taketa D, Shirer AE, Beer S, Yee AX, Voehringer DW, Felsher DW.
Nat Med.
2009;
15
(5):
566-71
-
On being metachromatic: mystique and misunderstanding in mastocytosis.
Gotlib J,
Am J Hematol.
2009;
84
(12):
779-81
-
RNAi screen for rapid therapeutic target identification in leukemia patients.
Tyner JW,
Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, O'Hare T, Heinrich MC, Druker BJ.
Proc Natl Acad Sci U S A.
2009;
106
(21):
8695-700
-
When yellow jackets attack: recurrent and severe anaphylactic reactions to insect bites and stings.
Pollyea DA,
George TI, Corless C, Gotlib J.
Am J Hematol.
2009;
84
(12):
843-6
-
Antiangiogenic therapy in myelodysplastic syndromes: is there a role?
Oh ST,
Gotlib J.
Curr Hematol Malig Rep.
2008;
3
(1):
10-8
-
Chronic eosinophilic leukemia/hypereosinophilic syndrome.
Gotlib J,
Cancer Treat Res.
2008:
142
69-106
-
Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias.
Gotlib J,
Cools J.
Leukemia.
2008;
22
(11):
1999-2010
-
Gene expression and pathway analysis of immune thrombocytopenic purpura.
Sood R,
Wong W, Gotlib J, Jeng M, Zehnder JL.
Br J Haematol.
2008;
140
(1):
99-103
-
Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.
Geron I,
Abrahamsson AE, Barroga CF, Kavalerchik E, Gotlib J, Hood JD, Durocher J, Mak CC, Noronha G, Soll RM, Tefferi A, Kaushansky K, Jamieson CH.
Cancer Cell.
2008;
13
(4):
321-30
-
A patient with paroxysmal nocturnal hemoglobinuria, T cell large granular lymphocyte clonal expansion, and monoclonal gammopathy of undetermined significance.
Fukumoto JS,
Gotlib J.
Am J Hematol.
2006;
81
(11):
870-4
-
Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis.
Lay M,
Mariappan R, Gotlib J, Dietz L, Sebastian S, Schrijver I, Zehnder JL.
J Mol Diagn.
2006;
8
(3):
330-4
-
Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.
Gotlib J,
Cross NC, Gilliland DG.
Best Pract Res Clin Haematol.
2006;
19
(3):
535-69
-
KIT mutations in mastocytosis and their potential as therapeutic targets.
Gotlib J,
Immunol Allergy Clin North Am.
2006;
26
(3):
575-92
-
Use of urine flow cytometry to verify relapse of Burkitt's lymphoma in the genitourinary system.
Dormady SP,
Mariappan MR, Kao D, Gotlib J.
J Clin Oncol.
2006;
24
(27):
4515-6
-
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.
Gotlib J,
Berubé C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutré SE.
Blood.
2005;
106
(8):
2865-70
-
Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.
Gotlib J,
Curr Hematol Rep.
2005;
4
(1):
77-84
-
Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.
Gotlib J,
Acta Haematol.
2005;
114
(1):
7-25
-
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.
Jamieson CH,
Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers CL, Weissman IL.
N Engl J Med.
2004;
351
(7):
657-67
-
Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
Coutré S,
Gotlib J.
Semin Cancer Biol.
2004;
14
(4):
307-15
-
Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
Coutré S,
Gotlib J.
Semin Cancer Biol.
2004;
14
(1):
23-31
-
The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
Gotlib J,
Cools J, Malone JM, Schrier SL, Gilliland DG, Coutré SE.
Blood.
2004;
103
(8):
2879-91
-
Novel biospecific agents for the treatment of myelodysplastic syndromes.
Gotlib J,
Greenberg PL.
J Natl Compr Canc Netw.
2003;
1
(4):
473-80
Help